Three independent discounted-cash-flow-style models value Bristol-Myers Squibb Company every trading day. 1 of 3 currently price BMY above its market price.
| Free Cash Flow model | $120.04 |
| Excess Profit model | $-10.94 |
| Residual Earnings model | $18.78 |
| Dividend Discount model | $106.07 |
| Piotroski F-Score | 8 / 9 |
| Return on invested capital | +16.5% |
| Net debt / EBITDA | 1.7× |
| Gross margin | +71.1% |
| Revenue CAGR | +1.4% |
| Cash conversion | 2.0× |
| Dividend yield | +4.2% |
| Buyback yield | -0.3% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open BMY in StockKitty